EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial

Chen Zhang, Xu Chang, Liyang Chen, Hang Wang, Ge Feng, Wei Zheng, Linfeng Li, Wei Xu, Xiangdong Qi, Xuan Jiang, Xiao Long, Nanze Yu und 3 weitere

Aesthetic Plastic Surgery · 2026

DOI: 10.1007/s00266-025-05494-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Aesthetic Plastic Surgery, 2026. Verfasst von Chen Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Peking University Third Hospital, Haidian District, 49 North Garden Road, Beijing, 100191, China. Hauptthemen laut MEDLINE: Nasolabial Fold, Acellular Dermis, Skin Aging, Dermal Fillers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nasolabial folds (NLFs) are prominent facial lines that deepen with age and may adversely affect facial aesthetics and psychosocial confidence. Injectable fillers, including micronized acellular dermal matrix (mADM), offer minimally invasive correction; however, clinical evidence for mADM’s safety and efficacy remains limited. We conducted a double-blind, multicenter, randomized controlled trial to compare an mADM filler (Regenfil) with a regulatory agency–approved cross-linked collagen filler (Sunmax Collagen Implant I-Plus).

Methods

Adults aged ≥18 years with Wrinkle Severity Rating Scale (WSRS) grade 3 or 4 NLFs were randomized to receive mADM or collagen. Six weeks after the initial treatment, a protocol-defined supplemental injection was permitted if additional correction was needed. Outcomes were assessed 6 weeks, 3 months, and 6 months after the last treatment. Efficacy endpoints included blinded-evaluator WSRS, Global Aesthetic Improvement Scale (GAIS) rated by injectors and participants, and participant satisfaction. The prespecified primary endpoint was the percentage of participants achieving a >1-grade WSRS improvement simultaneously on both left and right NLFs. Safety was evaluated by monitoring device-related adverse events and local injection-site reactions.

Results

Of 202 randomized participants, 175 completed all required follow-ups for safety and efficacy (mADM, n=86; collagen, n=89). The mADM group required lower mean filling volumes and fewer supplemental injections than the collagen group ( P 0.05). At 6 months, efficacy was 70.9% with mADM and 69.7% with collagen ( P >0.05). Apart from GAIS and participant satisfaction at 6 weeks, which favored collagen, no statistically significant differences were observed between groups across other efficacy endpoints and timepoints. The most common adverse events were hardening, redness, and skin discoloration at injection sites, occurring at similar frequencies in both groups ( P >0.05). Early local reactions such as swelling and pain were more frequent with mADM ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasolabial FoldAcellular DermisSkin AgingDermal FillersCosmetic TechniquesHumansFemaleDouble-Blind MethodMiddle AgedMaleAdultTreatment OutcomePatient SatisfactionCollagenAgedEsthetics

Stichwörter der Autor:innen

Aesthetic rejuvenationFiller injectionMicronized acellular dermal matrix (mADM)Nasolabial folds (NLF)Randomized controlled trial (RCT)

Substanzen

Dermal FillersCollagen

Autor:innen und Institutionen

  • Department of Plastic Surgery, Peking University Third Hospital, Haidian District, 49 North Garden Road, Beijing, 100191, China.
  • Department of Plastic Surgery, West China Hospital of Stomatology, Sichuan University, 14, Section 3, Renmin South Road, Chengdu, 610041, China.
  • Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, 95 Yongan Li, Xicheng District, Beijing, 100050, China.
  • Department of Plastic Surgery, Zhujiang Hospital of Southern Medical University, 253 Industrial Avenue, Haizhu District, Guangzhou, 510000, China.
  • Department of Plastic and Aesthetic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 41, Damucang Hutong, Xicheng District, Beijing, 100032, China.
  • Beijing Ruijian High-Tech Biological Technology Co., Ltd, Room 202, Building 15, 1, Chaoqian Road, Changping District, Beijing, 102200, China.

Zitieren

APA

Zhang, C., Chang, X., Chen, L., Wang, H., Feng, G., Zheng, W., Li, L., Xu, W., Qi, X., Jiang, X., Long, X., Yu, N., Chen, L., Long, N., & Bi, H. (2026). Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial. Aesthetic Plastic Surgery. https://doi.org/10.1007/s00266-025-05494-4

Vancouver

Zhang C, Chang X, Chen L, Wang H, Feng G, Zheng W, et al. Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial. Aesthetic Plastic Surgery. 2026. doi:10.1007/s00266-025-05494-4

BibTeX
@article{Zhang2026,
  author = {Zhang, Chen and Chang, Xu and Chen, Liyang and Wang, Hang and Feng, Ge and Zheng, Wei and Li, Linfeng and Xu, Wei and Qi, Xiangdong and Jiang, Xuan and Long, Xiao and Yu, Nanze and Chen, Lu and Long, Nannan and Bi, Hongsen},
  title = {Safety and Efficacy of Micronized Acellular Dermal Matrix Injection for Correction of Moderate to Severe Nasolabial Folds: A Double-Blind, Multicenter, Randomized Controlled, Non-inferior Clinical Trial},
  journal = {Aesthetic Plastic Surgery},
  year = {2026},
  doi = {10.1007/s00266-025-05494-4}
}
Kostenlos starten →